Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005834 · ClinicalTrials.gov registry record · Phase 3
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT00005834 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 19 participants.
The verdict
NCT00005834, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without thalidomide in treating patients who have refractory multiple myeloma.
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG etoposide
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2000-04 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005834
The ClinicalTrials.gov registry entry for NCT00005834 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00005834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005834 about?
NCT00005834 is a clinical study titled "S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide f...
What is the current status of trial NCT00005834?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2000-04. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00005834?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), dexamethasone (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005834?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.